TLRs1-10 Protein Expression in Circulating Human White Blood Cells during Bacterial and COVID-19 Infections.
Louise Chomel, Mathieu Vogt, Julien Demiselle...
https://pubmed.ncbi.nlm.nih.gov/38461810Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID03559569
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
Led by University Hospital, Strasbourg, France · Updated on 2025-03-10
520
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying circulatory shock (CS), a sudden and life-threatening condition causing organ failure. Although critical care advancements have improved early survival, patients who survive CS face higher risks of new infections and cardiovascular problems. The study aims to understand how premature aging (senescence) of blood vessel lining cells (endothelial cells) and immune cells contributes to these complications after CS. The study will include 500 patients hospitalized in intensive care units with circulatory shock and 20 healthy volunteers for comparison. Researchers will collect biological samples and use noninvasive methods to assess heart and blood vessel function and stiffness. This observational study will evaluate the presence of senescent cell features and their role in secondary infections and cardiovascular events. Participants will be followed for up to five years to monitor the development of cardiovascular problems and infections. The main measurement is the detection of senescent traits in leukocytes and endothelial cells after one year. Data on heart function, arterial stiffness, and immune cell aging will be gathered through various assessments. This long-term follow-up aims to improve understanding of disease processes and guide future prevention strategies.
CONDITIONS
Brief Title
Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Diagnosed with circulatory shock
- Have health care insurance
You will not qualify if you...
- Patients who refuse to participate in clinical research
- Pregnant women
- Breastfeeding women
- Patients under a protective order
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Sample Collection
Duration - 1 year
Participants provide biological samples to evaluate endothelial and leukocyte senescence using noninvasive and sensitive methods.
1 to 2 visits depending on participant group
Long-term Monitoring
Duration - Up to 5 years
Participants are monitored for incidence of cardiovascular events and secondary infections following initial assessments.
Periodic follow-up visits
Trial Site Locations
Total: 1 location
1
Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC
Strasbourg, France, 67091
Actively Recruiting
Loading map...
Research Team
M
Morgane CLERC
M
Madoé JULIANS
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here